Case 3: Faricimab in a neovascular nAMD patient with persistent fluid

Dr. Khanani discusses how switching to faricimab helped resolve persistent intraretinal and subretinal fluid in a patient and extended treatment intervals leading to decreased patient burden.

EP: 1.Insights on efficacy and safety of faricimab

EP: 2.Case 1: Faricimab in a high-need neovascular nAMD patient

EP: 3.Case 2: Faricimab in treatment naïve neovascular nAMD patient

Now Viewing

EP: 4.Case 3: Faricimab in a neovascular nAMD patient with persistent fluid

Sponsored by Roche